GSTM1 and hematologic disorder: A landmark randomized phase 3 trial had found that the restrictive threshold (transfuse if Hb < 7 g/dL) was non-inferior to the liberal threshold (transfuse if Hb < 9 g/dL) in patients with hematologic malignancy, requiring HCT, resulting in no significant differences in clinical outcomes [95].